Cartesian Therapeutics (NASDAQ: RNAC) announced results from its Phase 2 trial of Descartes-08 in systemic lupus erythematosus patients, showing all ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE